Rifaximin treatment reduced serum levels of several proinflammatory interleukins (IL) such as IL22 and CCL20 in both groups of patients, while IL17 and CXCL13 were only reduced in patients without metabolic syndrome manifestations. Here, IL17A is linked to metabolic syndrome.